4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000082
PRESIDENT AND CFO sold 42,000 shares at an average $115.39 ($4,846,508)
- PRESIDENT AND CFO acquired 42,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 98,383 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 106,383 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Option exercise 10b5-1 | +12,000 | $5.35 | $64,200 | 118,383 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Option exercise 10b5-1 | +14,000 | $5.35 | $74,900 | 132,383 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Sale 10b5-1 | −36,114 | $115.26 | $4,162,608 | 96,269 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Sale 10b5-1 | −5,886 | $116.19 | $683,900 | 90,383 | D |
| Derivatives | |||||||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 312,827 | D | ||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 304,827 | D | ||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −12,000 | 292,827 | D | ||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-10-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −14,000 | 278,827 | D | ||
| Open-market sales · 42,000 sh · avg $115.39 · $4,846,508 | |||||||
Loading xslF345X05/wk-form4_1729627909.xml…